Значения термина locoregionally advanced на английском

Patients: one hundred eighty-four patients with locoregionally advanced head and neck cancer.

The modern treatment of locoregionally advanced disease often requires a multimodality combination approach.

We performed a phase II trial to evaluate a docetaxel-based regimen in locoregionally advanced esophageal cancer.

Twenty-three newly diagnosed, locoregionally advanced NPC patients were enrolled, of whom 20 received a single-dose of TIL infusion following CCRT.

We aimed to identify a gene expression pattern for individual distant metastatic risk assessment in patients with locoregionally advanced nasopharyngeal carcinoma.

Conclusions: among patients successfully treated for locoregionally advanced cancers of the head and neck, several factors correlate with speaking and swallowing outcomes.

Methods and materials: The TP53 mutation and HPV status were analyzed in 78 cases of locoregionally advanced OPSCC.

Conclusions: This trial demonstrated the significant survival benefits of concurrent chemotherapy plus adjuvant chemotherapy in patients with locoregionally advanced NPC in endemic regions of China.

To identify differential biology and novel therapeutic targets for both entities, we determined mutations and copy-number aberrations in a large cohort of locoregionally advanced HNSCC.

Conclusion: This paclitaxel-based treatment regimen for locoregionally advanced esophageal cancer produced increased toxicity with no improvement in results when compared with our previous 5-FU experience.

Locoregionally advanced squamous cell carcinomas of the head and neck continue to be a major clinical problem.